Literature DB >> 24013097

miRNA-141, downregulated in pancreatic cancer, inhibits cell proliferation and invasion by directly targeting MAP4K4.

Gang Zhao1, Bo Wang, Yang Liu, Jun-Gang Zhang, Shi-Chang Deng, Qi Qin, Kui Tian, Xiang Li, Shuai Zhu, Yi Niu, Qiong Gong, Chun-You Wang.   

Abstract

miRNAs are associated with various types of cancer due to their ability to affect expression of genes that modulate tumorigenesis. In this study, we explored the role of miR-141 in pancreatic cancer. The analysis of clinical characteristics showed that miR-141 was significantly downregulated in tissues and cell lines of pancreatic cancer. Moreover, the decreased miR-141 level was significantly associated with tumor size and TNM stage, as well as lymph node and distant metastasis. Meanwhile, both Kaplan-Meier and multivariate survival analysis showed decreased miR-141 were associated with overall survival. Overexpression of miR-141 in pancreatic cancer cells inhibited cell proliferation, clonogenicity, and invasion; induced G1 arrest and apoptosis; and enhanced chemosensitivity. To understand how miR-141 mediates the phenotype of pancreatic cancer cells, a bioinformatics tool was used to identify MAP4K4 as a potential target of miR-141. The Dual-Luciferase reporter gene assay showed that miR-141 binds directly to the 3'-untranslated region (3'UTR) of MAP4K4 to inhibit MAP4K4 expression. Western blot and quantitative real-time PCR (qRT-PCR) analyses revealed that MAP4K4 expression was inversely correlated with miR-141 expression both in pancreatic cancer samples and cell lines. Knockdown of MAP4K4 inhibited cell proliferation, clonogenicity, and invasion, induced G1 arrest and apoptosis, and enhanced chemosensitivity. In a nude mouse xenograft model, both overexpression of miR-141 and knockdown of MAP4K4 significantly repressed pancreatic cancer cell growth. Therefore, we conclude that miR-141 targets MAP4K4, acts as a tumor suppressor in pancreatic cancer cells, and may serve as a novel therapeutic agent for miRNA-based pancreatic cancer therapy. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24013097     DOI: 10.1158/1535-7163.MCT-13-0296

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  66 in total

Review 1.  Noncoding RNAs and pancreatic cancer.

Authors:  Juan-Fei Peng; Yan-Yan Zhuang; Feng-Ting Huang; Shi-Neng Zhang
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

2.  MicroRNA-141 and microRNA-146b-5p inhibit the prometastatic mesenchymal characteristics through the RNA-binding protein AUF1 targeting the transcription factor ZEB1 and the protein kinase AKT.

Authors:  Huda H Al-Khalaf; Abdelilah Aboussekhra
Journal:  J Biol Chem       Date:  2014-09-26       Impact factor: 5.157

Review 3.  Contribution of bioinformatics prediction in microRNA-based cancer therapeutics.

Authors:  Jasjit K Banwait; Dhundy R Bastola
Journal:  Adv Drug Deliv Rev       Date:  2014-11-06       Impact factor: 15.470

4.  Preclinical evaluation of the supercritical extract of azadirachta indica (neem) leaves in vitro and in vivo on inhibition of prostate cancer tumor growth.

Authors:  Qiang Wu; Manish Kohli; H Robert Bergen; John C Cheville; R Jeffrey Karnes; Hong Cao; Charles Y F Young; Donald J Tindall; Mark A McNiven; Krishna Vanaja Donkena
Journal:  Mol Cancer Ther       Date:  2014-03-27       Impact factor: 6.261

5.  Arsenic-exposed Keratinocytes Exhibit Differential microRNAs Expression Profile; Potential Implication of miR-21, miR-200a and miR-141 in Melanoma Pathway.

Authors:  Horacio Gonzalez; Carolina Lema; Robert A Kirken; Rosa A Maldonado; Armando Varela-Ramirez; Renato J Aguilera
Journal:  Clin Cancer Drugs       Date:  2015

Review 6.  Non-coding RNAs in pancreatic cancer: challenges and opportunities for clinical application.

Authors:  V Taucher; H Mangge; J Haybaeck
Journal:  Cell Oncol (Dordr)       Date:  2016-04-08       Impact factor: 6.730

7.  microRNA-622 acts as a tumor suppressor in hepatocellular carcinoma.

Authors:  Wei-Hua Song; Xiao-Jun Feng; Shao-Juan Gong; Jian-Ming Chen; Shou-Mei Wang; Dong-Juan Xing; Ming-Hua Zhu; Shu-Hui Zhang; Ai-Min Xu
Journal:  Cancer Biol Ther       Date:  2015       Impact factor: 4.742

8.  Insights into the Role of microRNAs in Pancreatic Cancer Pathogenesis: Potential for Diagnosis, Prognosis, and Therapy.

Authors:  Mohammad Aslam Khan; Haseeb Zubair; Sanjeev Kumar Srivastava; Seema Singh; Ajay Pratap Singh
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

Review 9.  Mini but mighty: microRNAs in the pathobiology of periodontal disease.

Authors:  Moritz Kebschull; Panos N Papapanou
Journal:  Periodontol 2000       Date:  2015-10       Impact factor: 7.589

Review 10.  MicroRNAs as emerging biomarkers and therapeutic targets for pancreatic cancer.

Authors:  Marion Gayral; Sébastien Jo; Naima Hanoun; Alix Vignolle-Vidoni; Hubert Lulka; Yannick Delpu; Aline Meulle; Marlène Dufresne; Marine Humeau; Maël Chalret du Rieu; Barbara Bournet; Janick Sèlves; Rosine Guimbaud; Nicolas Carrère; Louis Buscail; Jérôme Torrisani; Pierre Cordelier
Journal:  World J Gastroenterol       Date:  2014-08-28       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.